- Home
- LPCN vs INTS Comparison
LPCN vs INTS Comparison
Compare LPCN & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- INTS
- Stock Information
- Founded
- LPCN 1997
- INTS 2012
- Country
- LPCN United States
- INTS United States
- Employees
- LPCN N/A
- INTS N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- INTS Health Care
- Exchange
- LPCN Nasdaq
- INTS Nasdaq
- Market Cap
- LPCN 36.8M
- INTS 43.7M
- IPO Year
- LPCN N/A
- INTS 2023
- Fundamental
- Price
- LPCN $5.16
- INTS $2.58
- Analyst Decision
- LPCN Strong Buy
- INTS Strong Buy
- Analyst Count
- LPCN 1
- INTS 2
- Target Price
- LPCN $10.00
- INTS $8.50
- AVG Volume (30 Days)
- LPCN 26.5K
- INTS 17.8K
- Earning Date
- LPCN 11-07-2024
- INTS 11-13-2024
- Dividend Yield
- LPCN N/A
- INTS N/A
- EPS Growth
- LPCN N/A
- INTS N/A
- EPS
- LPCN N/A
- INTS N/A
- Revenue
- LPCN $7,922,926.00
- INTS N/A
- Revenue This Year
- LPCN N/A
- INTS N/A
- Revenue Next Year
- LPCN N/A
- INTS N/A
- P/E Ratio
- LPCN N/A
- INTS N/A
- Revenue Growth
- LPCN N/A
- INTS N/A
- 52 Week Low
- LPCN $2.38
- INTS $2.15
- 52 Week High
- LPCN $11.79
- INTS $11.44
- Technical
- Relative Strength Index (RSI)
- LPCN 49.88
- INTS 28.08
- Support Level
- LPCN $4.64
- INTS $2.50
- Resistance Level
- LPCN $5.40
- INTS $3.30
- Average True Range (ATR)
- LPCN 0.51
- INTS 0.22
- MACD
- LPCN -0.07
- INTS -0.04
- Stochastic Oscillator
- LPCN 34.48
- INTS 8.90
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.